David C Dalgarno
Overview
Explore the profile of David C Dalgarno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monteiro da Silva G, Cui J, Dalgarno D, Lisi G, Rubenstein B
Nat Commun
. 2024 Apr;
15(1):3089.
PMID: 38600144
No abstract available.
2.
Monteiro da Silva G, Cui J, Dalgarno D, Lisi G, Rubenstein B
Nat Commun
. 2024 Mar;
15(1):2464.
PMID: 38538622
This paper presents an innovative approach for predicting the relative populations of protein conformations using AlphaFold 2, an AI-powered method that has revolutionized biology by enabling the accurate prediction of...
3.
Monteiro da Silva G, Cui J, Dalgarno D, Lisi G, Rubenstein B
ArXiv
. 2023 Aug;
PMID: 37547653
This paper presents a novel approach for predicting the relative populations of protein conformations using AlphaFold 2, an AI-powered method that has revolutionized biology by enabling the accurate prediction of...
4.
Monteiro da Silva G, Cui J, Dalgarno D, Lisi G, Rubenstein B
bioRxiv
. 2023 Aug;
PMID: 37546747
This paper presents a novel approach for predicting the relative populations of protein conformations using AlphaFold 2, an AI-powered method that has revolutionized biology by enabling the accurate prediction of...
5.
Huang W, Li F, Gong Y, Zhang Y, Youngsaye W, Xu Y, et al.
Bioorg Med Chem Lett
. 2022 Nov;
80:129084.
PMID: 36423823
In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this...
6.
Zech S, Kohlmann A, Zhou T, Li F, Squillace R, Parillon L, et al.
J Med Chem
. 2015 Dec;
59(2):671-86.
PMID: 26700752
Choline kinase α (ChoKα) is an enzyme involved in the synthesis of phospholipids and thereby plays key roles in regulation of cell proliferation, oncogenic transformation, and human carcinogenesis. Since several...
7.
Kohlmann A, Zech S, Li F, Zhou T, Squillace R, Commodore L, et al.
J Med Chem
. 2013 Jan;
56(3):1023-40.
PMID: 23302067
Lactate dehydrogenase A (LDH-A) catalyzes the interconversion of lactate and pyruvate in the glycolysis pathway. Cancer cells rely heavily on glycolysis instead of oxidative phosphorylation to generate ATP, a phenomenon...
8.
Zech S, Carr M, Mohemmad Q, Narasimhan N, Murray C, Rozamus L, et al.
J Antibiot (Tokyo)
. 2011 Jul;
64(9):649-54.
PMID: 21792211
We describe the identification of novel rapamycin derivatives present as low-level impurities in active pharmaceutical ingredients using an integrated, multidisciplinary approach. Rapamycin, a fermentation-derived natural product is itself used clinically...
9.
Thomas M, Huang W, Wen D, Zhu X, Wang Y, Metcalf C, et al.
Bioorg Med Chem Lett
. 2011 May;
21(12):3743-8.
PMID: 21561767
Ponatinib (AP24534) was previously identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML....
10.
Zhou T, Commodore L, Huang W, Wang Y, Thomas M, Keats J, et al.
Chem Biol Drug Des
. 2010 Dec;
77(1):1-11.
PMID: 21118377
The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has necessitated the development of new mutation-resistant inhibitors, most recently...